Expert insights. Personalized for you.
would have enough doses to vaccinate 300 million Americans by the end of the July With the orders now finalized, President Biden said the U.S. MORE
Easing patent protections, though, isn't likely to translate to an immediate boost in vaccine supply The shift in U.S. policy might not undermine future research as the drug industry claims. MORE
While health officials have documented more cases of a rare blood clotting syndrome associated with J&J's vaccine, a CDC committee supported use of the shot with an added warning MORE
The EMA has reiterated the benefits of the shot outweigh the risks, but the safety concerns are another hurdle to the vaccine's rollout in Europe MORE
So far, both Pfizer's and Moderna's vaccines appear to work against more transmissible variants, but preparation is underway for the day they don't MORE
The government-funded trial will evaluate the effects of mixing vaccines and varying timing between shots MORE
QUICK READ: Pfizer is already positioning their Covid vaccine as a yearly maintenance shot. Make no mistake; the drug companies will make a lot of money from these vaccines while they continue to hide profits offshore. ( If Pfizer raised the price of its coronavirus vaccine from $19.50 MORE
The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it MORE
Vaccinations are expected to begin within days of the historic decision, which follows early approvals in the U.K., Canada and Mexico MORE
SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. MORE
QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. The rush to develop a COVID-19 vaccine is well underway because there are billions of dollars in profits at stake. As I See It COVID Vaccine MORE
SUMMARY: Johnson & Johnson and AstraZeneca publicly committed to not profiting off their products during the pandemic; Pfizer and Moderna made no such pledge and are already planning ways to make more money from their Covid vaccines. The post Profiteering off a Covid vaccine. MORE
QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. in the news COVID Vaccine MORE
QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?” MORE
You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. However, there’s still a long way to go before researchers can be certain that this vaccine is indeed as effective as promised. MORE
A panel of vaccine and infectious disease experts will publicly vet the drugmakers' study results on Thursday. Follow the discussion along with BioPharma Dive reporters here MORE
These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on MyLocalStudy.com. MORE
Results from previous trials have raised questions about the vaccine and how well it works. Data from a large U.S. study could help clear up the confusion MORE
Canada was set to help CanSino produce its experimental shot as part of a deal to run what would've been the country's first coronavirus vaccine study MORE
The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday MORE
SUMMARY: The numbers game for COVOD-19 vaccine makers has started but what most of the public, and the media, don’t understand is that the preliminary numbers don’t mean a damn thing until they are peer-reviewed. As I See It COVID Vaccine MORE
A deal to fill vials of Pfizer and BioNTech's vaccine could be the first of several Novartis signs to help others make COVID-19 treatments MORE
The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year MORE
Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots MORE
Credit: Dennis Horvath, University of Konstanz One shot, protected forever: This would be a dream come true regarding influenza vaccinations. So far, vaccination against influenza did not provide a lasting protection. MORE
pharmaceutical industry, came out in favor of waiving intellectual property protections for coronavirus vaccines. The Biden administration, siding with some world leaders over the U.S. MORE
The agency's emergency clearance makes J&J's vaccine the third available in the U.S., adding much-needed reinforcements at a critical time MORE
The milestone filing could pave the way for the shot's use beyond the pandemic and give employers the legal heft to require vaccination, a key step toward herd immunity in the U.S. MORE
The emergency clearance greatly expands the pool of people who can be vaccinated in the U.S. just as some states are beginning to report waning demand MORE
Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations MORE
A vaccine co-developed by the U.K. academic center and the Maryland biotech could be the first to meet the WHO's efficacy target for a malaria vaccine MORE
A call by regulators to stop J&J vaccinations won't dramatically disrupt supply in the U.S. But changes in labeling are possible, as is a renewed debate over vaccine hesitancy MORE
study participant led to a worldwide pause in vaccinations, the country's drugs regulator and an independent committee allowed testing to resume Six days after a worrisome illness in a U.K. MORE
Importantly, the study committee hasn't had reason to pause vaccinations in the trial, something AstraZeneca and the University of Oxford recently reported in tests of their vaccine MORE
An interim analysis conducted after 94 cases of COVID-19 in Pfizer and BioNTech's large study found their vaccine to be more than 90% effective MORE
But differences between each vaccine could still prove crucial The companies' early success helps validate an industry-wide bet to target the coronavirus' spike protein. MORE
The drugmaker, one of the largest vaccine developers globally, won't move forward with either of two candidates it's been testing after disappointing data in early trials MORE
One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses MORE
(Mckinsey) Much of the prevailing market research on COVID-19 vaccination frames sentiment as “likely,” “unlikely,” or “neutral.” Their research has found that consumers’ attitudes towards receiving a COVID-19 vaccine fall into three primary segments. in the news COVID Vaccine MORE
The FDA and CDC recommended halting vaccinations while they investigate six cases of unusual blood clots in women given the company's shot MORE
Agency scientists noted the shot's strong protection against severe COVID-19, even for the virus variant first detected in South Africa and known to weaken vaccine potency MORE
Updated study results show Moderna's coronavirus vaccine was strongly protective against COVID-19 through six months. But executives outlined contingency plans in case those effects fade MORE
The vaccine's efficacy was higher in the U.S., but lower in Latin America and South Africa, where new, more infectious virus variants are circulating MORE
The French drugmaker, having hit delays with its own coronavirus shot, agreed to manufacture over 100 million doses of Pfizer and BioNTech's vaccine for supply in Europe MORE
Vaccination Related Topics World of DTC Marketing
MARCH 25, 2021
SUMMARY: Johnson & Johnson and AstraZeneca publicly committed to not profiting off their products during the pandemic; Pfizer and Moderna made no such pledge and are already planning ways to make more money from their Covid vaccines. The post Profiteering off a Covid vaccine.
Bio Pharma Dive
MAY 10, 2021
The emergency clearance greatly expands the pool of people who can be vaccinated in the U.S. just as some states are beginning to report waning demand
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
NOVEMBER 10, 2020
You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. However, there’s still a long way to go before researchers can be certain that this vaccine is indeed as effective as promised.
World of DTC Marketing
NOVEMBER 16, 2020
SUMMARY: The numbers game for COVOD-19 vaccine makers has started but what most of the public, and the media, don’t understand is that the preliminary numbers don’t mean a damn thing until they are peer-reviewed. As I See It COVID Vaccine
Bio Pharma Dive
MAY 4, 2021
The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year
Bio Pharma Dive
FEBRUARY 27, 2021
The agency's emergency clearance makes J&J's vaccine the third available in the U.S., adding much-needed reinforcements at a critical time
Bio Pharma Dive
FEBRUARY 19, 2021
The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday
Bio Pharma Dive
DECEMBER 30, 2020
The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it
Bio Pharma Dive
APRIL 23, 2021
A vaccine co-developed by the U.K. academic center and the Maryland biotech could be the first to meet the WHO's efficacy target for a malaria vaccine
World of DTC Marketing
JANUARY 8, 2021
SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others.
Bio Pharma Dive
MAY 6, 2021
Easing patent protections, though, isn't likely to translate to an immediate boost in vaccine supply The shift in U.S. policy might not undermine future research as the drug industry claims.
Bio Pharma Dive
APRIL 13, 2021
The FDA and CDC recommended halting vaccinations while they investigate six cases of unusual blood clots in women given the company's shot
Bio Pharma Dive
JANUARY 28, 2021
So far, both Pfizer's and Moderna's vaccines appear to work against more transmissible variants, but preparation is underway for the day they don't
Bio Pharma Dive
FEBRUARY 9, 2021
Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots
My Local Study
OCTOBER 1, 2020
These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on MyLocalStudy.com.
Bio Pharma Dive
JANUARY 25, 2021
The drugmaker, one of the largest vaccine developers globally, won't move forward with either of two candidates it's been testing after disappointing data in early trials
Bio Pharma Dive
APRIL 1, 2021
One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses
World of DTC Marketing
JULY 22, 2020
QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?”
NY Times
MAY 5, 2021
pharmaceutical industry, came out in favor of waiving intellectual property protections for coronavirus vaccines. The Biden administration, siding with some world leaders over the U.S.
Bio Pharma Dive
FEBRUARY 24, 2021
Agency scientists noted the shot's strong protection against severe COVID-19, even for the virus variant first detected in South Africa and known to weaken vaccine potency
Bio Pharma Dive
NOVEMBER 9, 2020
An interim analysis conducted after 94 cases of COVID-19 in Pfizer and BioNTech's large study found their vaccine to be more than 90% effective
Bio Pharma Dive
JANUARY 29, 2021
A deal to fill vials of Pfizer and BioNTech's vaccine could be the first of several Novartis signs to help others make COVID-19 treatments
World of DTC Marketing
JULY 28, 2020
QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. in the news COVID Vaccine
Bio Pharma Dive
FEBRUARY 4, 2021
The government-funded trial will evaluate the effects of mixing vaccines and varying timing between shots
Bio Pharma Dive
DECEMBER 9, 2020
A panel of vaccine and infectious disease experts will publicly vet the drugmakers' study results on Thursday. Follow the discussion along with BioPharma Dive reporters here
Bio Pharma Dive
MARCH 8, 2021
Results from previous trials have raised questions about the vaccine and how well it works. Data from a large U.S. study could help clear up the confusion
Bio Pharma Dive
APRIL 23, 2021
While health officials have documented more cases of a rare blood clotting syndrome associated with J&J's vaccine, a CDC committee supported use of the shot with an added warning
Bio Pharma Dive
JANUARY 29, 2021
The vaccine's efficacy was higher in the U.S., but lower in Latin America and South Africa, where new, more infectious virus variants are circulating
Bio Pharma Dive
APRIL 9, 2021
The EMA has reiterated the benefits of the shot outweigh the risks, but the safety concerns are another hurdle to the vaccine's rollout in Europe
World of DTC Marketing
AUGUST 3, 2020
QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. The rush to develop a COVID-19 vaccine is well underway because there are billions of dollars in profits at stake. As I See It COVID Vaccine
Bio Pharma Dive
MAY 7, 2021
The milestone filing could pave the way for the shot's use beyond the pandemic and give employers the legal heft to require vaccination, a key step toward herd immunity in the U.S.
Bio Pharma Dive
NOVEMBER 11, 2020
But differences between each vaccine could still prove crucial The companies' early success helps validate an industry-wide bet to target the coronavirus' spike protein.
Bio Pharma Dive
AUGUST 27, 2020
Canada was set to help CanSino produce its experimental shot as part of a deal to run what would've been the country's first coronavirus vaccine study
Bio Pharma Dive
APRIL 14, 2021
Updated study results show Moderna's coronavirus vaccine was strongly protective against COVID-19 through six months. But executives outlined contingency plans in case those effects fade
Bio Pharma Dive
FEBRUARY 12, 2021
would have enough doses to vaccinate 300 million Americans by the end of the July With the orders now finalized, President Biden said the U.S.
Bio Pharma Dive
SEPTEMBER 12, 2020
study participant led to a worldwide pause in vaccinations, the country's drugs regulator and an independent committee allowed testing to resume Six days after a worrisome illness in a U.K.
Bio Pharma Dive
APRIL 13, 2021
A call by regulators to stop J&J vaccinations won't dramatically disrupt supply in the U.S. But changes in labeling are possible, as is a renewed debate over vaccine hesitancy
Scienmag
MARCH 12, 2021
Credit: Dennis Horvath, University of Konstanz One shot, protected forever: This would be a dream come true regarding influenza vaccinations. So far, vaccination against influenza did not provide a lasting protection.
Bio Pharma Dive
JULY 31, 2020
Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations
Bio Pharma Dive
DECEMBER 11, 2020
Vaccinations are expected to begin within days of the historic decision, which follows early approvals in the U.K., Canada and Mexico
World of DTC Marketing
APRIL 2, 2021
QUICK READ: Pfizer is already positioning their Covid vaccine as a yearly maintenance shot. Make no mistake; the drug companies will make a lot of money from these vaccines while they continue to hide profits offshore. ( If Pfizer raised the price of its coronavirus vaccine from $19.50
Bio Pharma Dive
SEPTEMBER 15, 2020
Importantly, the study committee hasn't had reason to pause vaccinations in the trial, something AstraZeneca and the University of Oxford recently reported in tests of their vaccine
Bio Pharma Dive
JANUARY 26, 2021
The French drugmaker, having hit delays with its own coronavirus shot, agreed to manufacture over 100 million doses of Pfizer and BioNTech's vaccine for supply in Europe
195 
Let's personalize your content